NASDAQ:BLTE Belite Bio Q3 2026 Earnings Date & Estimates $154.19 +11.00 (+7.68%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$154.04 -0.15 (-0.09%) As of 11/6/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Belite Bio is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Belite Bio in Q3 2026Belite Bio is expected to post earnings of -$0.7863 per share. In the same quarter a year earlier Belite Bio reported -$0.65 per share. Belite Bio last reported on August 12, 2026, posting -$0.54 per share and beating the -$0.73 consensus estimate. Belite Bio has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.7863Prior-Year EPS-$0.65Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.54 (Beat by +$0.19)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Belite Bio Q3 2026 Earnings FAQ When does Belite Bio report Q3 2026 earnings? Belite Bio (NASDAQ:BLTE) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Belite Bio's Q3 2026 earnings call? Belite Bio's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Belite Bio? Analysts expect Belite Bio to post earnings of -$0.7863 per share for Q3 2026. Belite Bio Earnings HeadlinesBelite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial ResultsNovember 5 at 8:00 AM | globenewswire.comBelite Bio Inc ADROctober 31, 2026 | in.investing.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th. | Behind the Markets (Ad)Belite Bio Elevates Nasdaq Listing As Company Advances Retinal Disease PipelineOctober 19, 2026 | rttnews.comBelite Bio Announces Uplisting to the Nasdaq Global Select MarketOctober 19, 2026 | globenewswire.comBelite Bio Files Regulatory Applications For Tinlarebant In Singapore, UK, SwitzerlandOctober 15, 2026 | rttnews.comSee More Belite Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Belite Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Belite Bio and other key companies, straight to your email. Email Address About Belite BioBelite Bio (NASDAQ:BLTE), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for eye diseases that can cause severe vision loss. The company’s research is centered on therapies that target the visual cycle, a biological process involved in the production and recycling of vitamin A in the retina. Belite Bio’s lead product candidate is tinlarebant, also known as LBS-008. The orally administered therapy is designed to reduce the formation and accumulation of toxic vitamin A byproducts in the eye. The company is developing tinlarebant for Stargardt disease, an inherited retinal disorder, and geographic atrophy associated with age-related macular degeneration. Headquartered in San Diego, California, Belite Bio conducts research and clinical development activities intended to support the potential use of its therapies in patients worldwide. The company’s pipeline is primarily focused on retinal diseases for which significant unmet medical needs remain.View Belite Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Sandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
